Corvus Pharmaceuticals, Inc.

Informe acción NasdaqGM:CRVS

Capitalización de mercado: US$515.4m

Corvus Pharmaceuticals Dirección

Dirección controles de criterios 3/4

El CEO de Corvus Pharmaceuticals es Rick Miller , nombrado en Feb 2014, tiene una permanencia de 10.75 años. compensación anual total es $1.32M, compuesta por 8.3% salario y 91.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.82% de las acciones de la empresa, por valor de $14.55M. La antigüedad media del equipo directivo y de la junta directiva es de 4.9 años y 9.5 años, respectivamente.

Información clave

Rick Miller

Chief Executive Officer (CEO)

US$1.3m

Compensación total

Porcentaje del salario del CEO8.3%
Permanencia del CEO10.8yrs
Participación del CEO2.8%
Permanencia media de la dirección4.9yrs
Promedio de permanencia en la Junta Directiva9.5yrs

Actualizaciones recientes de la dirección

Recent updates

Corvus Pharmaceuticals: The Market Likes The Story

Nov 13

Corvus Pharmaceuticals: Soquelitinib's High Stakes In PTCL Therapy

Sep 02

Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Mar 06
Will Corvus Pharmaceuticals (NASDAQ:CRVS) Spend Its Cash Wisely?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Oct 23
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

May 16
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Invest In Growth?

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Dec 05
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Corvus' partner Angel Pharma gets nod to start phase 1/1b trial of cancer therapy in China

Sep 26

We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Aug 14
We're Keeping An Eye On Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Rate

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

Apr 05
Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth

We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Dec 15
We're Hopeful That Corvus Pharmaceuticals (NASDAQ:CRVS) Will Use Its Cash Wisely

Checking In On Corvus Pharmaceuticals

Dec 10

Corvus: Surging On AstraZeneca CD73 Success With Key Data Readout Looming

Sep 22

We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Aug 26
We Think Corvus Pharmaceuticals (NASDAQ:CRVS) Can Afford To Drive Business Growth

Corvus Pharmaceuticals initiated buy at Cantor with a Street-high target

May 27

Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

May 08
Is Corvus Pharmaceuticals (NASDAQ:CRVS) In A Good Position To Deliver On Growth Plans?

The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Feb 19
The Co-Founder of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), Richard Miller, Just Bought 8.5% More Shares

Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Feb 07
Here's Why We're Watching Corvus Pharmaceuticals' (NASDAQ:CRVS) Cash Burn Situation

Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Dec 16
Here's What Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) Shareholder Ownership Structure Looks Like

Corvus Pharmaceuticals EPS misses by $0.06

Oct 29

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rick Miller en comparación con los beneficios de Corvus Pharmaceuticals?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2024n/an/a

-US$57m

Jun 30 2024n/an/a

-US$23m

Mar 31 2024n/an/a

-US$25m

Dec 31 2023US$1mUS$110k

-US$27m

Sep 30 2023n/an/a

-US$30m

Jun 30 2023n/an/a

-US$39m

Mar 31 2023n/an/a

-US$41m

Dec 31 2022US$524kUS$300k

-US$41m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$37m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$905kUS$300k

-US$43m

Sep 30 2021n/an/a

-US$7m

Jun 30 2021n/an/a

-US$6m

Mar 31 2021n/an/a

-US$5m

Dec 31 2020US$1mUS$300k

-US$6m

Sep 30 2020n/an/a

-US$44m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$48m

Dec 31 2019US$1mUS$300k

-US$47m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$46m

Mar 31 2019n/an/a

-US$44m

Dec 31 2018US$1mUS$300k

-US$47m

Sep 30 2018n/an/a

-US$48m

Jun 30 2018n/an/a

-US$51m

Mar 31 2018n/an/a

-US$54m

Dec 31 2017US$1mUS$302k

-US$56m

Compensación vs. Mercado: La compensación total de Rick($USD1.32M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.24M).

Compensación vs. Ingresos: La compensación de Rick ha aumentado mientras la empresa no es rentable.


CEO

Rick Miller (73 yo)

10.8yrs

Permanencia

US$1,321,351

Compensación

Dr. Richard A. Miller, also known as Rick, M.D., serves as Director of BrainScope Company Inc. since September 2023. He is a Co-Founder of Corvus Pharmaceuticals, Inc. and has been its Chief Executive Offi...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Richard Miller
Co-Founder10.8yrsUS$1.32m2.82%
$ 14.5m
Peter Thompson
Co-Founder & Independent Directorno dataUS$95.35ksin datos
Leiv Lea
Chief Financial Officer10yrsUS$660.76k0.45%
$ 2.3m
William Jones
Senior Vice President of Pharmaceutical Development4.9yrsUS$616.26k0.25%
$ 1.3m
James Rosenbaum
Senior Vice President of Research2.3yrssin datossin datos
Jeffrey Arcara
Chief Business Officerless than a yearsin datossin datos

4.9yrs

Permanencia media

67yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CRVS se considera experimentado (4.9 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Richard Miller
Co-Founder10.8yrsUS$1.32m2.82%
$ 14.5m
Peter Thompson
Co-Founder & Independent Director10yrsUS$95.35ksin datos
Elisha Gould
Independent Director10yrsUS$101.35ksin datos
Linda Grais
Independent Director5.8yrsUS$97.35k0.016%
$ 82.4k
Ian T. Clark
Independent Director7.8yrsUS$93.35ksin datos
Scott William Morrison
Independent Director8.9yrsUS$109.35ksin datos

9.5yrs

Permanencia media

66.5yo

Promedio de edad

Junta con experiencia: La junta directiva de CRVS se considera experimentada (9.5 años de antigüedad promedio).